Rebreath Solution for Inhalation 175 mg/3 ml contains Revefenacin, a long-acting muscarinic antagonist (LAMA) used for the maintenance treatment of chronic obstructive pulmonary disease (COPD). This inhalation solution is designed for use with a nebulizer, providing direct delivery of the medication to the lungs for rapid and effective bronchodilation. Rebreath helps relax airway muscles, improves airflow, reduces breathlessness, and enhances overall lung function in patients with COPD.

Revefenacin works by selectively blocking muscarinic M3 receptors in the airway smooth muscles. By inhibiting these receptors, the drug prevents acetylcholine-mediated bronchoconstriction, resulting in sustained relaxation of the airways. Unlike short-acting bronchodilators, Rebreath provides long-lasting effects with once-daily administration, improving patient convenience and adherence to therapy.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Composition

Each 3 ml ampoule contains:

• Revefenacin 175 mg for inhalation via nebulizer

Indications

Rebreath Solution for Inhalation is indicated for:

• Maintenance treatment of chronic obstructive pulmonary disease (COPD) in adults

• Management of airflow obstruction associated with COPD

• Improvement of lung function, exercise tolerance, and symptom control in patients with moderate to severe COPD

• Reduction of exacerbation risk in long-term COPD management

Mechanism of Action

Revefenacin, the active ingredient in Rebreath, works by:

• Blocking muscarinic M3 receptors in airway smooth muscle

• Preventing acetylcholine-mediated bronchoconstriction

• Causing sustained bronchodilation, reducing airway resistance

• Enhancing airflow, oxygen exchange, and patient respiratory comfort

Direct inhalation ensures maximum local effect in the lungs with minimal systemic exposure, reducing the risk of adverse effects compared to oral administration.

Dosage and Administration

• The recommended dose is 175 mg once daily, administered via a nebulizer.

• Use the solution as prescribed, ensuring the full dose is inhaled for optimal therapeutic benefit.

• The solution should be used with an approved jet nebulizer and mouthpiece; ensure the device is clean before use.

• Do not mix with other medications unless directed by a healthcare provider.

• Follow proper inhalation technique to achieve maximum drug delivery to the lungs.

Precautions and Warnings

• Use with caution in patients with narrow-angle glaucoma, urinary retention, or severe cardiac disease.

• Inform your doctor if you have kidney or liver impairment.

• Not intended for relief of acute bronchospasm or sudden breathing attacks; a short-acting bronchodilator should be used for such episodes.

• Monitor for signs of allergic reactions or paradoxical bronchospasm.

• Pregnant or breastfeeding women should use only under medical supervision.

Possible Side Effects

Rebreath Solution is generally well tolerated. Common side effects may include:

• Cough or throat irritation

• Dry mouth

• Headache or dizziness

• Nausea

Rare but serious adverse effects may include:

• Paradoxical bronchospasm

• Allergic reactions (rash, swelling, or difficulty breathing)

• Tachycardia or palpitations

Seek immediate medical attention if severe reactions occur.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Storage Instructions

• Store below 30°C in a cool, dry place.

• Protect from light and moisture.

• Keep out of reach of children.

• Use each ampoule immediately after opening.

Conclusion

Rebreath Solution for Inhalation 175 mg/3 ml (Revefenacin) is an effective once-daily LAMA therapy for the maintenance treatment of COPD. It improves airflow, reduces symptoms, and enhances quality of life for patients with chronic lung disease. Proper use with a nebulizer ensures targeted delivery and optimal therapeutic outcomes.